文献速递妇科肿瘤

仑伐替尼联合帕博利珠单抗治疗晚期子宫内膜癌:一项多中心、开放标签、单臂、2期试验的中期分析

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2019-03-25

这项在美国11个中心开展的开放标签、单臂、2期研究,纳入54例晚期子宫内膜癌患者(未筛选微卫星不稳定或PD-L1状态),给予仑伐替尼20 mg每日口服联合帕博利珠单抗200 mg每3周静脉注射。中期分析中,第24周客观缓解率为39.6%(95% CI 26.5-54.0),安全性特征与两种药物单药既往报告相似,但甲状腺功能减退频率增加。作者认为该联合方案可能代表新的潜在治疗选择,并正在随机3期研究中进行评估。

要点

  • 第24周客观缓解率为39.6%(95% CI 26.5-54.0),基于53例可分析患者。
  • 严重治疗相关不良事件发生于16例(30%)患者,报告1例治疗相关死亡(颅内出血)。
  • 最常见的任何级别治疗相关不良事件为高血压(58%)、疲乏(55%)、腹泻(51%)和甲状腺功能减退(47%)。

核心结论

  • 仑伐替尼联合帕博利珠单抗在晚期复发性子宫内膜癌患者中显示出抗肿瘤活性,安全性特征与两种药物单药既往报告相似,但甲状腺功能减退频率增加。
  • 作者认为该联合方案可能代表该患者人群的一种新的潜在治疗选择,并正在随机3期研究中进行评估。

研究设计与样本

  • 这是一项在美国11个中心开展的开放标签、单臂、2期研究,患者接受仑伐替尼20 mg每日口服联合帕博利珠单抗200 mg每3周静脉注射。
  • 纳入年龄18岁及以上、转移性子宫内膜癌(未筛选微卫星不稳定或PD-L1状态)、ECOG体能状态0或1、既往系统治疗不超过两种、根据irRECIST有可测量病灶、预期寿命12周及以上的患者。
  • 2015年9月10日至2017年7月24日期间共入组54例患者,其中53例纳入分析。

主要发现

  • 截至抗肿瘤活性数据截止日期2017年12月15日,中位研究随访为13.3个月(IQR 6.7-20.1)。
  • 21例(39.6% [95% CI 26.5-54.0])患者在第24周达到客观缓解。
  • 严重治疗相关不良事件发生于16例(30%)患者,报告1例治疗相关死亡(颅内出血)。
  • 最常见的任何级别治疗相关不良事件为高血压(31例 [58%])、疲乏(29例 [55%])、腹泻(27例 [51%])和甲状腺功能减退(25例 [47%]);最常见的3级治疗相关不良事件为高血压(18例 [34%])和腹泻(4例 [8%])。
  • 未报告4级治疗相关不良事件;5例(9%)患者因治疗相关不良事件停止研究治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lenvatinib is a multikinase inhibitor of VEGFR1, VEGFR2, and VEGFR3, and other receptor tyrosine kinases. Pembrolizumab, an antibody targeting PD-1, has moderate efficacy in biomarker-unselected endometrial cancer. We aimed to assess the combination of lenvatinib plus pembrolizumab in patients with advanced endometrial carcinoma, after establishing the maximum tolerated dose in a phase 1b study. METHODS: In this open-label, single-arm, phase 2 study done at 11 centres in the USA, eligible patients were aged 18 years or older and had metastatic endometrial cancer (unselected for microsatellite instability or PD-L1), had an Eastern Cooperative Oncology Group performance status of 0 or 1, had received no more than two previous systemic therapies, had measurable disease according to the immune-related Response Evaluation Criteria In Solid Tumors (irRECIST), and had a life expectancy of 12 weeks or longer. Patients received 20 mg oral lenvatinib daily plus 200 mg intravenous pembrolizumab every 3 weeks. Treatment continued until disease progression, development of unacceptable toxic effects, or withdrawal of consent. The primary endpoint of this interim analysis was the proportion of patients with an objective response at week 24 as assessed by investigators according to irRECIST in the per-protocol population. This trial is registered with ClinicalTrials.gov, number NCT02501096. FINDINGS: Between Sept 10, 2015, and July 24, 2017, 54 patients were enrolled, 53 of whom were included in the analysis. At the cutoff date for anti-tumour activity data (Dec 15, 2017), median study follow-up was 13·3 months (IQR 6·7-20·1). 21 (39·6% [95% CI 26·5-54·0]) patients had an objective response at week 24. Serious treatment-related adverse events occurred in 16 (30%) patients, and one treatment-related death was reported (intracranial haemorrhage). The most frequently reported any-grade treatment-related adverse events were hypertension (31 [58%]), fatigue (29 [55%]), diarrhoea (27 [51%]), and hypothyroidism (25 [47%]). The most common grade 3 treatment-related adverse events were hypertension (18 [34%]) and diarrhoea (four [8%]). No grade 4 treatment-related adverse events were reported. Five (9%) patients discontinued study treatment because of treatment-related adverse events. INTERPRETATION: Lenvatinib plus pembrolizumab showed anti-tumour activity in patients with advanced recurrent endometrial cancer with a safety profile that was similar to those previously reported for lenvatinib and pembrolizumab monotherapies, apart from an increased frequency of hypothyroidism. Lenvatinib plus pembrolizumab could represent a new potential treatment option for this patient population, and is being investigated in a randomised phase 3 study. FUNDING: Eisai and Merck.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019. PMID: 30922731. doi:10.1016/S1470-2045(19)30020-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。